MedPath

ebulized furosemide as adjunctive therapy in patients with stable chronic obstructive pulmonary disease : A randomized controlled trial

Not Applicable
Not yet recruiting
Conditions
Respiratory
Registration Number
PACTR202106917652038
Lead Sponsor
Medical Research Institute Alexandria University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
All
Target Recruitment
100
Inclusion Criteria

Stable (Not exacerbating) COPD patients documented by the pulmonologist
- FEV1, FVC, (FEV1/FVC) less than 70%
- Irreversible response to inhaled ß-agonist (FEV1i ncrease <12% and <200 cc after15min from baseline)
- Symptoms last about 5 years of breathlessness and, productive cough

Exclusion Criteria

Patients with history of other lung diseases such as pneumonia, idiopathic pulmonary fibrosis, consolidation, congestive heart failure, exacerbated, asthma or asthma-COPD overlap.
Smoking more than 15 packs/year
using furosemide and other diuretics

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.